SESNのチャート
SESNの企業情報
| symbol | SESN |
|---|---|
| 会社名 | Sesen Bio Inc （イレブン・バイオセラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Sesen Bio Inc. formerly Eleven Biotherapeutics Inc. is a late-stage clinical company that provides targeted protein therapeutics (TPT) platform. The Company is focused on developing antibody-drug conjugate (ADC) therapies for the treatment of cancer. Its product pipeline includes Vicinium Vicinium in combination with checkpoint inhibator durvalumab and VB6-845d. The Company’s lead program Vicinium is a fusion protein in Phase III development for the treatment of non-muscle invasive bladder cancer (NMIBC). It targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent cytotoxin Pseudomonas Exotoxin A (ETA) directly to cancer cells. イレブン・バイオセラピュ―ティクスは、米国のバイオ医薬品企業。AMP-Rxと呼ばれる独自のタンパク質工学プラットフォ―ムを使用し、目の疾患の治療用にタンパク質治療薬の開発を行う。ドライアイ疾患およびアレルギ―性結膜炎の局所治療としての製品候補の開発を手掛ける。前臨床製品候補には、糖尿病性黄斑浮腫やブドウ膜炎の治療薬がある。 Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company's lead program, Vicineum™, also known as VB4-845, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In December 2020, the Company completed the BLA submission for Vicineum to the FDA. Sesen Bio retains worldwide rights to Vicineum with the exception of Greater China and the Middle East and North Africa (MENA), for which the Company has partnered with Qilu Pharmaceutical and Hikma Pharmaceuticals, respectively, for commercialization. Vicineum is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of high-risk NMIBC. |
| 本社所在地 | 245 First Street Suite 1800 Cambridge MA 02142 USA |
| 代表者氏名 | Daniel S. Lynch ダニエルS.リンチ |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 617-444-8550 |
| 設立年月日 | 39479 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 17人 |
| url | www.elevenbio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/sesn |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -28.56800 |
| 終値（lastsale） | 1.84 |
| 時価総額（marketcap） | 141700238.16 |
| 時価総額 | 時価総額（百万ドル） 124.75780 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 61.79680 |
| 当期純利益 | 当期純利益（百万ドル） -28.57300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Sesen Bio Inc revenues decreased from $425K to $0K. Net loss decreased 3% to $12.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Loss from change in fair value of contin decrease of 27% to $2.7M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.54 to -$0.27. |
SESNのテクニカル分析
SESNのニュース
Sesen Bio Inc. (NASDAQ: SESN) Continues To Thrive In 2022, As Its Stock Is Down -7.36% Year-To-Date 2022/08/04 11:00:00 Marketing Sentinel
During the last session, Sesen Bio Inc. (NASDAQ:SESN)’s traded shares were 1.31 million, with the beta value of the company hitting 0.61. At the end of the trading day, the stock’s price was $0.75, reflecting an intraday loss of -3.30% or -$0.03. The 52-week high for the SESN share is $6.04, that puts it down … Sesen Bio Inc. (NASDAQ: SESN) Continues To Thrive In 2022, As Its Stock Is Down -7.36% Year-To-Date Read More »
Sesen Bio Inc. (NASDAQ: SESN): Overvalued Against Others? 2022/07/29 14:30:00 Stocks Register
Sesen Bio Inc. (NASDAQ:SESN) price on Thursday, July 28, rose 16.66% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $0.81. A look at the stock’s price movement, the close in the last trading session was $0.69, moving within a range at $0.6866 and $0.86. The beta value … Sesen Bio Inc. (NASDAQ: SESN): Overvalued Against Others? Read More »
Sesen Bio granted additional time period for regaining compliance 2022/07/27 12:47:07 Seeking Alpha
Nasdaq Listing Qualifications department notified Sesen Bio (SESN) that it has been granted a second 180-day grace period, or until Jan.23, 2023 for regaining compliance with the…
Surprising stocks: Sesen Bio, Inc. (NASDAQ:SESN 2.62%), Palatin Technologies, Inc. (AMEX:PTN 0.26%) 2022/07/22 01:15:39 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Surprising stocks: Sesen Bio, Inc. (NASDAQ:SESN 2.62%), Palatin Technologies, Inc. (AMEX:PTN 0.26%) appeared first on Stocks Equity .
Breathtaking stocks: Sesen Bio, Inc. (NASDAQ:SESN 3.42%), Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT -0.62%) 2022/07/21 01:20:52 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Breathtaking stocks: Sesen Bio, Inc. (NASDAQ:SESN 3.42%), Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT -0.62%) appeared first on Stocks Equity .
69 Biggest Movers From Yesterday 2022/06/10 08:15:13 Benzinga
Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS ) shares climbed 189.9% to close at $1.12 on Thursday. NextPlay Technologies, Inc. (NASDAQ: NXTP ) jumped 93.4% to close at $0.3503. DBV Technologies S.A. (NASDAQ: DBVT ) jumped 79.6% to close at $3.25. Applied UV, Inc. (NASDAQ: AUVI ) rose 55.4% to close at $2.75 after the company announced its distributor, M/S Novatek Pakistan, was awarded as the sole source provider of Airocide air purification systems for government hospitals. View, Inc. (NASDAQ: VIEW ) jumped 48% to settle at $2.56 on above-average volume. FingerMotion, Inc. (NASDAQ: FNGR ) gained 41.1% to close at $1.99. Mobiquity Technologies, Inc. (NASDAQ: MOBQ ) rose 40.5% to close at $1.16. Cardiff Oncology, Inc. (NASDAQ: CRDF ) gained 35.5% to settle at $2.25. Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE ) jumped 35.1% to settle at $1.29. Zynerba Pharmaceuticals files international patent application titled ''Cannabidiol For The Treatment Of Refractory Seizures.'' Eros Media World Plc (NYSE: EMWP ) rose 32.8% to close at $4.25.
Sesen Bio Reports First Quarter 2022 Financial Results and Business Update 2022/05/09 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the first quarter ended March 31, 2022. During the quarter, the Company continued to engage with the US Food and Drug Administration (FDA) to identify an anticipated regulatory path toward potential resubmission of a Biologics License Application (BLA) for Vicineum™ for the treat
Thinking about buying stock in Amarin, Iamgold, Amcor, Freshworks, or Sesen Bio? 2022/05/04 14:45:00 Benzinga
NEW YORK , May 4, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMRN, IAG, AMCR, FRSH, and SESN. … Full story available on Benzinga.com
The Daily Biotech Pulse: FDA''s AdComm For Acadia''s Pimavanserin, Review Issues For Spero''s Tebipenem Application, Cortexyme Layoffs 2022/05/03 13:01:06 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Acadia Announces FDA AdComm For Pimavanserin In Alzheimer''s-Related Psychosis The FDA''s Psychopharmacologic Drugs Advisory Committee will review Acadia Pharmaceuticals Inc (NASDAQ: ACAD ) resubmitted supplemental marketing application for pimavanserin on June 17 . The application seeks approval for pimavanserin for hallucinations and delusions associated with Alzheimer''s disease psychosis. The target action date for the application is Aug. 4. Ipsen, Exelixis'' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer The European Commission has approved Ipsen SA''s (OTC: IPSEY ) Cabometyx (cabozantinib) as monotherapy in differentiated thyroid carcinoma (DTC) setting. The approval covers adult patients with locally advanced or metastatic DTC that is refractory or not eligible for radioactive iodine who have progressed during or after systemic therapy. This EC approval follows the FDA approval announced by Exelixis Inc (NASDAQ: EXEL ) in September 2021 of Cabometyx for adult and pediatric patients with locally advanced or metastatic DTC.
Ensnaring stocks: Creatd, Inc. (NASDAQ:CRTD 4.72%), Sesen Bio, Inc. (NASDAQ:SESN 1.46%) 2022/04/15 19:11:00 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Ensnaring stocks: Creatd, Inc. (NASDAQ:CRTD 4.72%), Sesen Bio, Inc. (NASDAQ:SESN 1.46%) appeared first on Stocks Equity .
Sesen Bio: Q4 Earnings Insights 2022/02/28 15:41:30 Benzinga
Sesen Bio (NASDAQ: SESN ) reported its Q4 earnings results on Monday, February 28, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Sesen Bio beat estimated earnings by 157.14%, reporting … Full story available on Benzinga.com
Sesen Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Anticipated Regulatory Path Forward for the Company’s Lead Product Candidate, Vicineum™ 2022/02/28 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the fourth quarter and full year ended December 31, 2021. During the fourth quarter, the Company worked with the US Food and Drug Administration (FDA) to identify an anticipated regulatory path toward potential resubmission of a Biologics License Application (BLA) for the Company
Volume Buzz: Sesen Bio, Inc. (NASDAQ:SESN), Lloyds Banking Group plc (NYSE:LYG) 2021/12/24 04:31:38 Stock Equity
Sesen Bio, Inc. (NASDAQ:SESN) with the stream of -0.70% also noticed, India Lloyds Banking Group plc (NYSE:LYG) encountered a rapid change of 2.03% in the last hour of Thursdays trading The post Volume Buzz: Sesen Bio, Inc. (NASDAQ:SESN), Lloyds Banking Group plc (NYSE:LYG) appeared first on Stocks Equity .
Lifshitz Law Firm, P.C. Announces Investigations of Generac Holdings Inc. (NYSE: GNRC), Katapult Holdings, Inc. (NASDAQGM: KPLT), PayPal Holdings, Inc. (NASDAQGS: PYPL), and SeSen Bio, Inc. (NASDAQGM: SESN) 2021/12/23 17:47:00 GlobeNewswire
NEW YORK, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Generac Holdings Inc. (NYSE: GNRC)
Sesen Bio Inc. (NASDAQ: SESN)s Gain Of 1.99% Profited Investors 2021/12/22 16:30:00 Stocks Register
Sesen Bio Inc. (NASDAQ:SESN) traded at $0.89 at close of the session on Tuesday, 12/21/21, made an upward move of 1.99% on its previous days price. Looking at the stock we see that its previous close was $0.87 and the beta (5Y monthly) reads 0.50 with the days price range being $0.8525 $0.9008. In Sesen Bio Inc. (NASDAQ: SESN)s Gain Of 1.99% Profited Investors Read More »